ReviewVaccines2021
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis.Journal of translational medicine · 2025Review
- Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.Annals of clinical and translational neurology · 2024Observational
- Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets.Annals of clinical and translational neurology · 2024Article
- Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review.Neurology and therapy · 2023Review
- Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.European neurology · 2023Review
- COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.European journal of neurology · 2022Article
- Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.Neurology and therapy · 2022Review
- Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.Vaccines · 2022Review
- Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.Drug design, development and therapy · 2022Review
- Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine.Frontiers in immunology · 2022Article
- Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.Frontiers in immunology · 2022Article
- Multiple Sclerosis, COVID-19 and Vaccines: Making the Point.Neurology and therapy · 2021Review
- Administration of COVID-19 vaccines in immunocompromised patients.International immunopharmacology · 2021Review
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.Journal of neurology, neurosurgery, and psychiatry · 2021Review
- Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.Multiple sclerosis and related disorders · 2021Article
- Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2021Article
- Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.Vaccines · 2021Review
- COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.Multiple sclerosis and related disorders · 2021Article
- Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care.Frontiers in digital health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.